WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
Cambodia commemorates 2 Chinese martyrs killed in peacekeeping mission 31 years agoVenezuelan president warns against new threats from USThe Piano review: This show's standout performer? A romantic OAP with dementia, writes ROLAND WHITEBookstore makes reading accessible to rural areas in Inner MongoliaPutin calls for deEdwards and Towns lead Timberwolves into the 2nd round of the NBA playoffs for 1st time since 2004EastEnders star Shona McGarty reveals the real reason she quit the BBC soap after 16 yearsPromotional event helps Chinese films 'go global'Xi, Biden hold phone talksChina's envoy in Washington urges US to avoid Thucydides Trap in bilateral ties
3.2217s , 6501.6171875 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,Global Grounds news portal